title: iPAD or PADi-'tablets' with therapeutic disease potential?
abstract: Over the last five years, a growing body of literature has strengthened the rationale for the involvement of PAD (protein arginine deiminase) enzymes in diverse diseases, through direct roles of citrullination in mechanisms such as neutrophil extracellular trap formation and immune complex formation. The recent development of inhibitors of the PAD family, coupled with the availability of mice genetically deficient in PAD2 or PAD4, has accelerated understanding of the role of these targets in varied disease models. This review surveys the recent literature to confirm the therapeutic potential of PAD inhibitors as a new class of drugs to treat human autoimmune disease.
authors.affiliation: Epinova Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GSK, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK. Electronic address: huw.d.lewis@gsk.com.
authors.forename: Huw D
authors.initials: HD
authors.lastname: Lewis
authors.affiliation: Padlock Therapeutics, Inc., 200 Cambridge Park Drive, Cambridge, MA 02140, United States.
authors.forename: Mariana
authors.initials: M
authors.lastname: Nacht
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D050197:Atherosclerosis / Q000188:drug therapy*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D051379:Mice; D008822:Mice, Transgenic; D008838:Microcomputers; D013927:Thrombosis / Q000188:drug therapy*